ArticlePloS one2025
Trends in rheumatoid arthritis burden in China and globally, 1990-2021: A longitudinal study based on the GBD database.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sinomenine ameliorates rheumatoid arthritis in rodent models: a systematic review and meta-analysis of anti-inflammatory and joint-protective effects.Frontiers in pharmacology · 2026Pooled it
- Antirheumatic Medication Calendar Significantly Improves Adherence in First-Time Methotrexate Users: A Prospective, Single-Blind, Randomized Controlled Trial.Patient preference and adherence · 2025Trial
- Fraxin Attenuates Rheumatoid Arthritis by Regulating Macrophage Polarization and Inhibiting Fibroblast-like Synoviocyte Proliferation.International journal of molecular sciences · 2026Article
- Astragaloside IV Modulates the Immune Response in Rheumatoid Arthritis and is Associated with Inhibition of the NAV2-Wnt/β-Catenin Signaling Cascade.Journal of inflammation research · 2026Article
- Disparities in Knowledge, Attitudes, and Practices Regarding Rheumatoid Arthritis Between Han and She Ethnic Groups in Ningde City, Eastern Fujian, China: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Global, Regional, and National Burden of Chronic Myeloid Leukemia Among the Elderly from 1990 to 2021: A Population-Based Epidemiological Analysis.Clinical epidemiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a chronic autoimmune disease that imposes significant health and economic burdens worldwide, particularly in developing countries such as China.
methodIn this study, the Global Burden of Disease, The GBD database system stratified the incidence,prevalence,death and disability-adjusted life years (DALYs) of RA in China and the world from 1990 to 2021 by age, sex and period. Joinpoint Regression Program 5.1.0 was then used to calculate average annual percent change (AAPC) and 95% confidence interval (95% confidence interval). CI) to identify trends in disease burden. In addition, data collation using WPS allows for the comparison of RA burdens across different age groups, genders and time points in China and globally, and the data is rigorously screened and processed to ensure accuracy and comparability.
resultsFrom 1990 to 2021, ASIR of RA in China increased by 0.54%, while the global ASIR rose by 0.41%.The number of RA cases in China increased cumulatively by 133%, compared to a global increase of 125.21%.Simultaneously, ASPR in China and globally increased by 17% and 14.44%, respectively.Regarding mortality, although the number of RA-related deaths increased in both China and globally, ASMR decreased by 26.23% in China and 22.86% globally.The trend in ASDR was consistent with ASMR, with declines of 0.40% in China and 1.46% globally.Furthermore, the study revealed significant gender disparities in RA both in China and globally, with women experiencing higher incidence, prevalence, mortality, and DALYs than men.The burden of RA increased significantly with age, particularly among middle-aged and older adults aged 45 and above.
conclusionOver the past 30 years, the burden of RA in China and globally has undergone significant changes.The study found that while RA related mortality and DALYs have slightly decreased in China and globally, the incidence and prevalence rates have continued to rise, particularly among women and middle-aged to elderly populations.Population aging and changes in lifestyle are key drivers of the increasing RA burden, with women showing higher susceptibility and burden due to their unique physiological characteristics and societal roles.The study highlights the need to strengthen early screening and intervention, optimize personalized treatment plans, and pay special attention to the unique needs of elderly and female populations.Additionally, promoting healthy lifestyles, improving primary healthcare services, and implementing supportive policies can effectively alleviate the health and socioeconomic burden of RA, ensuring a better quality of life for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.